In the SIBAMATE study, more than 60% of patients lost at least 5% of body weight after 3 months of using ...

Earlier in 2025, UNSW Sydney Ph.D. candidate Christina Schmidt submitted her thesis—from the deck of Australia's ...

The 2018 Lancet Commission,1 After asthma: redefining airways diseases, made clear recommendations to improve outcomes for ...

A shortage of laboratories, equipment and chemicals continues to undermine student performance in science subjects across the ...

Good morning, ladies and gentlemen, and welcome to aTyr Pharma conference call to review the top line results for the Phase III EFZO-FIT study of efzofitimod in pulmonary sarcoidosis. [Operator ...

VELA-1 and VELA-2 are two identical trials to evaluate the efficacy and safety of sonelokimab in adult participants with moderate to severe ...

In The Lancet Diabetes & Endocrinology, the STEP-UP T2D and STEP-UP trial groups present new findings on the efficacy and safety of higher-dose semaglutide (7·2 mg once weekly) in individuals with ...

Indianapolis: Eli Lilly and Company has announced that the European Commission (EC) has granted marketing authorization for ...

VELA-1 and VELA-2 are two identical trials to evaluate the efficacy and safety of sonelokimab in adult participants with moderate to severe hidradenitis suppurativa (HS) and the first Phase 3 ...

Bernstein 2nd Annual Global Healthcare Conference September 24, 2025 1:10 PM EDTCompany ParticipantsTom Cavanaugh - ...

By seeing yourself with grace, you create an internal safe space where you can grow. You can love your shadow and feel unconditional love, When you have your own back, you’ll feel braver to take the ...